NicOx's naproxcinod needs long-term safety data, US FDA panel says
This article was originally published in Scrip
Executive Summary
NicOx's anti-inflammatory agent naproxcinod requires further safety data, including long-term cardiovascular outcomes, prior to approval as an osteoarthritis treatment, the US FDA's outside advisors said at a meeting on 12 May.